Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adeno-carcinoma independently of driver mutations. Macheleidt IF1,2, Dalvi PS1,2, Lim SY1,2, et al. Mol Oncol. 2018 Sep 16. doi: 10.1002/1878-0261.12382. [Epub ahead of print]

CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression. Chen D1,2, Ma W3, Ke Z1, Xie F4. Cell Cycle. 2018 Sep 13:1-11. doi: 10.1080/15384101.2018.1515553. [Epub ahead of print]

Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro. Huang YP1, Jiang YW2, Chen HY2, et al. Anticancer Res. 2018 Sep;38(9):5165-5176. doi: 10.21873/anticanres.12839.

Effect of a pulmonary nodule fact sheet on patient anxiety and knowledge: a quality improvement initiative. Koroscil MT1, Bowman MH1, Morris MJ1, Skabelund AJ1, Hersh AM1. BMJ Open Qual. 2018 Sep 14;7(3):e000437. doi: 10.1136/bmjoq-2018-000437. eCollection 2018.

Implications of the Eighth Edition of the TNM Proposal: Invasive vs. Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma. Kameda K1, Eguchi T2, Lu S3, Qu Y4, Tan KS5, Kadota K6, Adusumilli PS7, Travis WD8. J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33037-5. doi: 10.1016/j.jtho.2018.08.2022. [Epub ahead of print]

Challenges to Educating Smokers About Lung Cancer Screening: a Qualitative Study of Decision Making Experiences in Primary Care. Greene PA1, Sayre G2,3, Heffner JL4, Klein DE5, Krebs P6,7, Au DH2,3,8, Zeliadt SB2,3. Cancer Educ. 2018 Sep 1. doi: 10.1007/s13187-018-1420-y. [Epub ahead of print]

Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting a treatment outcomes of non-small cell lung cancer. Machado-Rugolo J1, Fabro AT2, et al. Hum Pathol. 2018 Sep 12. pii: S0046-8177(18)30352-6. doi: 10.1016/j.humpath.2018.08.026. [Epub ahead of print]

Lung cancer screening: an emerging cancer control issue presents opportunities for an awareness campaign in rural Michigan. Springer SM1, McFall A2, Hager P2, Percy-Laury A3, Vinson CA3. Cancer Causes Control. 2018 Sep 18. doi: 10.1007/s10552-018-1080-6. [Epub ahead of print]

Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. Miller TE1, Yang M2, Bajor D3, et al. J Clin Pathol. 2018 Sep 18. pii: jclinpath-2018-205396. doi: 10.1136/jclinpath-2018-205396. [Epub ahead of print]

A national survey of primary care physicians: Perceptions and practices of low-dose CT lung cancer screening. Eberth JM1,2,3, McDonnell KK4, Sercy E1,2, Khan S2, Strayer SM5, Dievendorf AC4, Munden RF6, Vernon SW7. Prev Med Rep. 2018 May 22;11:93-99. doi: 10.1016/j.pmedr.2018.05.013. eCollection 2018 Sep.

Consolidation/Tumor Ratio on Chest Computed Tomography as Predictor of Postoperative Nodal Upstaging in Clinical T1N0 Lung Cancer. Moon Y1, Park JK2, Lee KY3, Namkoong M2, Ahn S2. World J Surg. 2018 Sep;42(9):2872-2878. doi: 10.1007/s00268-018-4543-8.

Video-assisted thoracoscopic surgery for lung cancer after induction therapy. Matsuoka K1, Yamada T1, Matsuoka T1, Nagai S1, Ueda M1, Miyamoto Y1. Asian Cardiovasc Thorac Ann. 2018 Sep 24:218492318804413. doi: 10.1177/0218492318804413. [Epub ahead of print]

Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients. Descarpentries C1, Leprêtre F2, Escande F1, et al. J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33038-7. doi: 10.1016/j.jtho.2018.08.2023. [Epub ahead of print]

Air Leak Management Program with Digital Drainage Reduces Length of Stay after Lobectomy. Mayor JM1, Lazarus DR2, Casal RF3, Omer S1, Preventza O4, Simpson K1, Jimenez E1, Cornwell LD5. Ann Thorac Surg. 2018 Sep 12. pii: S0003-4975(18)31246-3. doi: 10.1016/j.athoracsur.2018.07.029. [Epub ahead of print]

Postoperative complications decrease the cost-effectiveness of robotic-assisted lobectomy. Kneuertz PJ1, Singer E2, D’Souza DM2, Moffatt-Bruce SD2, Merritt RE2. Surgery. 2018 Sep 26. pii: S0039-6060(18)30560-9. doi: 10.1016/j.surg.2018.08.024. [Epub ahead of print]

Predicting Lung Function Following Lobectomy: A New Method to Adjust for Inherent Selection Bias. Ontiveros N1, Eapen-John D2, Osorio N1, et al. Respiration. 2018 Sep 26:1-12. doi: 10.1159/000490258. [Epub ahead of print]

Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis. Bains S1, Eguchi T2, Warth A3, et al. J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33119-8. doi: 10.1016/j.jtho.2018.09.008. [Epub ahead of print]

Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions. Yan YF1, Zheng YF2, Ming PP3, Deng XX1, Ge W4, Wu YG5. Brief Funct Genomics. 2018 Sep 20. doi: 10.1093/bfgp/ely029. [Epub ahead of print]

Progression-Free-Survival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450). De Ruysscher D1, Wanders R2, Hendriks LE3, et al. J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)30935-3. doi: 10.1016/j.jtho.2018.07.098. [Epub ahead of print]

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Park CK1, Cho HJ1, Choi YD2, Oh IJ1, Kim YC1. Cancer Res Treat. 2018 Sep 7. doi: 10.4143/crt.2018.387. [Epub ahead of print]

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. Ferrara R1, Mezquita L1, Texier M2, et al. JAMA Oncol. 2018 Sep 6. doi: 10.1001/jamaoncol.2018.3676. [Epub ahead of print]

Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer. Lin JJ1, Chin E1, Yeap BY1, et al. J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040-5. doi: 10.1016/j.jtho.2018.09.001. [Epub ahead of print]

Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma. Yu H1, Chen Z2, Ballman K2, et al. J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33116-2. doi: 10.1016/j.jtho.2018.09.006. [Epub ahead of print]

Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study. Gandara DR1, von Pawel J2, Mazieres J3, et al. J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33043-0. doi: 10.1016/j.jtho.2018.08.2027. [Epub ahead of print]

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Gadgeel S1, Peters S2, Mok T3, et al. Ann Oncol. 2018 Sep 12. doi: 10.1093/annonc/mdy405. [Epub ahead of print]

Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. Le X1, Puri S2, Negrao MV1, et al. Clin Cancer Res. 2018 Sep 18. pii: clincanres.1542.2018. doi: 10.1158/1078-0432.CCR-18-1542. [Epub ahead of print]

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. Stratmann JA1, Michels S2, Hornetz S3, et al. J Cancer Res Clin Oncol. 2018 Sep 22. doi: 10.1007/s00432-018-2754-x. [Epub ahead of print]

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer. Dagogo-Jack I1, Martinez P2, Yeap BY3, et al. Clin Cancer Res. 2018 Sep 17. pii: clincanres.2062.2018. doi: 10.1158/1078-0432.CCR-18-2062. [Epub ahead of print]

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. Goss GD1, Felip E2, Cobo M3, et al. JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. Wu B1, Gu X2, Zhang Q3, Xie F4,5,6,7. Oncologist. 2018 Sep 26. pii: theoncologist.2018-0150. doi: 10.1634/theoncologist.2018-0150. [Epub ahead of print]

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Yoo KH1,2, Lee SJ1, Cho J3, et al. Cancer Res Treat. 2018 Sep 3. doi: 10.4143/crt.2018.324. [Epub ahead of print]

Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go? Lim CK1, Wei YF2, Tsai MS3, Chen KY4, Shih JY5, Yu CJ5. Eur J Cancer. 2018 Sep 7;103:32-40. doi: 10.1016/j.ejca.2018.07.128. [Epub ahead of print]

Defining Optimal Comorbidity Measures for Patients with Early Stage Non-small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiation Therapy (SBRT). DeWees TA1, Nikitas J2, Rehman S3, Bradley JD2, Robinson CG2, Roach MC4. Pract Radiat Oncol. 2018 Sep 19. pii: S1879-8500(18)30264-9. doi: 10.1016/j.prro.2018.09.001. [Epub ahead of print]

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. Timmerman RD1,2, Paulus R3, Pass HI4, et al. JAMA Oncol. 2018 Sep 1;4(9):1263-1266. doi: 10.1001/jamaoncol.2018.1251.

The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors. Pike LRG1, Bang A2, Mahal BA3, et al. Int J Radiat Oncol Biol Phys. 2018 Sep 15. pii: S0360-3016(18)33755-6. doi: 10.1016/j.ijrobp.2018.09.010. [Epub ahead of print]

A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. Jahangiri P1, Pournazari K1, Torigian DA1, Werner TJ1, Swisher-McClure S2, Simone CB 2nd3, Alavi A1. Eur J Nucl Med Mol Imaging. 2018 Sep 18. doi: 10.1007/s00259-018-4154-5. [Epub ahead of print]

Clinical value of carcinoembryonic antigen for predicting the incidence of brain metastases and survival in small cell lung cancer patients treated with prophylactic cranial irradiation. Guo D#1,2, Jing W#2,3, Zhu H2, Li M2, Zou B2, Zhang Y2, Fu L2, Kong L2, Yue J2,4, Yu J2,4. Cancer Manag Res. 2018 Sep 4;10:3199-3205. doi: 10.2147/CMAR.S175043. eCollection 2018.

Will liquid biopsies improve outcomes for patients with small-cell lung cancer? Blackhall F1, Frese KK2, Simpson K2, Kilgour E2, Brady G2, Dive C3. Lancet Oncol. 2018 Sep;19(9):e470-e481. doi: 10.1016/S1470-2045(18)30455-8.

BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small-cell lung cancer. Chen W1, Hang Y1, Xu W1, Wu J2, Chen L1, Chen J1, Mao Y1, Song J1, Song J2, Wang H1. J Cell Biochem. 2018 Sep 11. doi: 10.1002/jcb.27548. [Epub ahead of print]

Targeted Therapy and Immune Therapy for Small Cell Lung Cancer. Gadgeel SM1. Curr Treat Options Oncol. 2018 Sep 10;19(11):53. doi: 10.1007/s11864-018-0568-3.

Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation. Zheng Y1,2,3, Wang L2,3, Zhao W1, Dou Y1, Lv W1, Yang H1, Sun Y1, Xing L4,5. Strahlenther Onkol. 2018 Sep 14. doi: 10.1007/s00066-018-1362-7. [Epub ahead of print]

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Wagner AH1, Devarakonda S2,3, Skidmore ZL1, et al. Nat Commun. 2018 Sep 17;9(1):3787. doi: 10.1038/s41467-018-06162-9.

Use of Dietary Supplements at a Comprehensive Cancer Center. Luo Q1, Asher GN2,3. J Altern Complement Med. 2018 Sep/Oct;24(9-10):981-987. doi: 10.1089/acm.2018.0183.

Self-efficacy, cancer-related fatigue, and quality of life in patients with resected lung cancer. Chen HL1, Liu K2, You QS2. Eur J Cancer Care (Engl). 2018 Sep 25:e12934. doi: 10.1111/ecc.12934. [Epub ahead of print]

Sleep Disordered Breathing Is Highly Prevalent in Patients with Lung Cancer: Results of the Sleep Apnea in Lung Cancer Study. Cabezas E1, Pérez-Warnisher MT2, Troncoso MF1, et al. Respiration. 2018 Sep 27:1-6. doi: 10.1159/000492273. [Epub ahead of print]

A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Bade BC1, Hyer JM2, Bevill BT2, Pastis A3, Rojewski AM2, Toll BA2, Silvestri GA2. Integr Cancer Ther. 2018 Sep;17(3):921-927. doi: 10.1177/1534735418781739. Epub 2018 Jun 14.

Complementary and Integrative Medicine to Reduce Adverse Effects of Anticancer Therapy. Rossi E1, Noberasco C1, Picchi M1, Stefano MD1, Rossi A1, Nurra L1, Ventura L2. J Altern Complement Med. 2018 Sep/Oct;24(9-10):933-941. doi: 10.1089/acm.2018.0143.

Complementary and Integrative Medicine in Lung Cancer: Questions and Challenges. Frenkel M1,2, Slater R1, Sapire K3, Sierpina V1. J Altern Complement Med. 2018 Sep/Oct;24(9-10):862-871. doi: 10.1089/acm.2018.0175.

Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial. Zhou Y1, Zhao B2, Wu W1, Yang X3, Long S1, Deng H1, He W1, Liao G1, Li Q1, Xie Z1. Trials. 2018 Sep 4;19(1):474. doi: 10.1186/s13063-018-2845-7.

Genome-wide association study of familial lung cancer. Byun J1, Schwartz AG2, Lusk C2, et al. Carcinogenesis. 2018 Sep 21;39(9):1135-1140. doi: 10.1093/carcin/bgy080.

Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Lou Y1, Dholaria B1, Soyano A1, et al. Cancer Med. 2018 Sep 2. doi: 10.1002/cam4.1749. [Epub ahead of print]